A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)

A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) Given Concomitantly With Menactra™ and Adacel™ in Preadolescents and Adolescents (11 to 15 Year Olds)

This study will evaluate the tolerability and immunogenicity of administration of the first dose of V503 at the same time as Menactra™ and Adacel™ versus administration of V503 one month prior to administration of Menactra™ and Adacel™.

Inclusion Criteria:

• Subject is in good health
• Subject's parent/legal guardian can read, understand, and complete the vaccine report card
• Subject is not sexually active and does not plan on becoming sexually active during the study
• Subject has received a documented full primary immunization series against diphtheria, tetanus, and pertussis (not in the last 5 years)

Exclusion Criteria:

• Subject has a known allergy to any vaccine component of V503, Menactra™, or Adacel™
• Subject has a condition that is a contraindication to vaccination with Menactra™ or Adacel™
• Subject has any coagulation disorder
• Female subject is pregnant
• Subject is immunocompromised or immunodeficient
• Subject has had a splenectomy
• Subject has received immunosuppressive therapies in the prior year
• Subject has received any immune globulin product or blood-derived product in the last 3 months
• Subject has received inactivated vaccines within 14 days or live vaccines within 21 days of the first study vaccination
• Subject has received a marketed HPV vaccine or has participation in an HPV vaccine trial
• Subject has received a meningococcal vaccine
• Subject has a fever >= 100F within 24 hours of vaccination
• Subject has a history of HPV